Buddy and Lifx had negative NPAT & EBITDA for 2018, therefore that would be a useless metric as well.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025